- Ongoing, recruitingTherapeutic confirmatory (Phase III)
Open-Label Safety, Pharmacokinetic, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) with Hereditary Angioedema Type I or II
This study is looking at a new medicine called sebetralstat (KVD900) for children aged 2-11 with a rare condition called Hereditary Angioedema (HAE) Types I or II. Doctors want to see how safe and effective this medicine is for them.
For: Hereditary Angioedema Type I or IIItaly · Germany · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients with Hereditary Angioedema Type I or II A Pharmacokinetic Subtrial in Adolescent Patients with Hereditary Angioedema Type I or II Participating in the KVD900-302 Trial
This study looks at how safe a medicine called KVD900 is when used long-term for swelling attacks in people with Hereditary Angioedema (HAE) Type 1 or 2. It also checks how the body handles the medicine in teenagers.
For: Hereditary Angioedema Type I or IISlovakia · Netherlands · Italy